Proton pump inhibitors are still overprescribed for hospitalized children

A Arnoux1, M Bailhache2, C Tetard1

  • 1Bordeaux University Hospital, Pediatric department, Pediatric Gastroenterology Unit, France.

Insights

Proton pump inhibitors are frequently prescribed for hospitalized children, but only 35% of prescriptions follow guidelines. Increased awareness of proton pump inhibitor recommendations is needed for pediatricians.

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Hospital Medicine

Background:

  • Proton pump inhibitor (PPI) use has surged globally.
  • Concerns regarding long-term PPI side effects necessitate adherence to prescribing guidelines.

Purpose of the Study:

  • To evaluate the adherence of PPI prescriptions to current recommendations in pediatric inpatient units.
  • To identify factors influencing PPI prescription compliance in children.

Main Methods:

  • A retrospective, observational study was conducted at Bordeaux University Hospital.
  • Medical records of 2237 children hospitalized between April 1 and September 30, 2019, were reviewed.
  • PPI prescriptions were compared against French and international guidelines.

Main Results:

  • Proton pump inhibitors were prescribed to 11% of hospitalized children, primarily for gastroesophageal reflux disease (47%) and peptic ulcer disease prevention (32.7%).
  • Overall compliance with recommendations was 34.5%, significantly lower in infants under 1 year (13.5%).
  • Compliance was higher for gastroesophageal reflux disease (48%) than for peptic ulcer disease prevention (5%).

Conclusions:

  • Proton pump inhibitor prescribing in hospitalized children frequently deviates from established guidelines.
  • Enhanced education on PPI recommendations for pediatricians is crucial to improve prescribing practices.
Abstract

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
558
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
595
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
153
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
586
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
636
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
313